Digital health innovations
We are actively seeking proven digital innovations that improve the health of people in the region and raise the quality, efficiency, safety and cost-effectiveness of delivering healthcare.
We are particularly interested to hear about innovations in the following categories:
  • Health maintenance - supporting people in maintaining their physical and mental wellbeing,
  • Prevention - alerting patients, carers or professionals when there are signs that things aren’t going well, and an intervention can prevent crises or emergencies
  • Access - providing more convenient and cost-effective ways for patients and professionals to interact. (e.g. remote monitoring or virtual consultations).
  • Learning and education - delivering information and knowledge to patients about their health or condition, or to professionals to support their continuous professional development
  • Pathways - providing tailored information to patients, carers and professionals on services to signpost people to the most appropriate place.  Ideally, this could be enhanced with real-time information about capacity.
  • Research - using digital tools to promote involvement in research & clinical trials, to streamline the capture of informed consent, and to capture research data more efficiently and conveniently.
  • Integration - tools that enable the secure, appropriate sharing of information between organisations (e.g. GPs and hospital clinicians) and sectors (e.g. NHS and Social Services) to allow patients to receive seamless care.
  • Data Visualisation - innovative ways of presenting information in a meaningful way to enable more informed decisions by patients and professionals.  This may involve aggregating data from different sources, reporting tools or graphic visualisations such as heat maps.

Ideas (Digital health)

Innovation 'Elevator Pitch':
NanoVation develops the SenseGuard - a respiratory monitoring solution for patients with chronic respiratory diseases, leveraging unique nano-sensor technology that enables continuous monitoring of lung function from tidal breathing.
Overview of Innovation:
SenseGuard™ is a reliable solution for monitoring patients with respiratory diseases, such as COPD. It is a wireless, wearable device that enables continuous and non-invasive monitoring of lung function of patients in both healthcare and home settings. SenseGuard™ is leveraging on a unique  technology - nano-based respiration sensors. Thanks to them, it seamlessly monitors patient’s normal (tidal) breathing, whether at rest or during activity. From it, the device extracts critical respiratory parameters (e.g. respiration rate, inhalation/exhalation times and ratio, apneas and more) for caregivers to check on patients' condition, manage their illness and early alert on pending exacerbations to allow treatment while the patient is still at home.

Competitive advantage: SenseGuard™  is a passive and continuous measurement of tidal breathing leveraging on a unique nanosensor technology, without any complicated actions required by the patient and/or operator. The device requires no patient cooperation or forced inhalation/exhalation test execution, unlike current technologies such as spirometry. SenseGuard™ monitoring test is not unpleasant or painful, which spikes up patient adherence to perform it. Its measurements are accurate in contrast to spirometry where the patient can do the breathing in a wrong manner and get a misleading result. SenseGuard™  can be used remotely or at the hospital to collect the patient’s pulmonary parameters. The patients' data is transmitted to a monitoring station, where the caregiver processes the information and responds with feedback about the management of the illness. SenseGuard™ allows to set thresholds in order to identify deviations from baseline values that can be indicative of an upcoming COPD exacerbation before it reaches critical stage. This contributes to reduced hospital admissions of patients and associated costs, while improving their health outcomes and quality of life.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
COPD management costs reduction
Reduction of hospitalizations
Reduction of hospital stay
Reduction of personnel burden
Improved quality of care
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
COPD management costs reduction
Improved quality of life for COPD patients
Current and planned activity: 
Looking to establish collaboration for clinical trials
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Read more
Hide details
Gregory Shuster 30/11/2019 - 16:58 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
We provide ethical software research and development services through partnership working, with health and social care providers. Bitjam focus on creating positive social impact.
Overview of Innovation:
Bitjam is a unique technology innovation service available for health and social care providers. We are an ethical company putting purpose before profit, focusing on creating a better society through strong partnership working, and technology innovation. Bitjam is renowned for bridging the gap between academia and frontline services. The company is led by Managing Director, Carl Plant, who has had many years experience of working as a healthcare professional. 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Digital health
Benefit to NHS:
Our previous partnership work has led to new technologies improving the lives of patients, through better communication and improved decision making for clinicians and patients. 
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
Improved services, cost savings. 
Current and planned activity: 
We prefer to choose projects that contribute to improving societal communication.
Currently, we are working on 'Smart with your Heart' Innovate UK testbed project. We facilitate their data analysis with a purpose-built data evaluation dashboard. This imports data from a hospital system, community services and 3 digital technologies project partners, aiming to see in real-time if the service is meeting its KPIs. It allows clinicians the ability to see how many patients are using the system and of those patients how many have been able to manage their condition in the community and prevent readmittance into hospital.
We are also working on an acute neonatal platform, that not only allows video conferencing for consultants but shows critical information for patient management. Enabling speedy patient referrals, transfer tracking in real-time, team availability and cot bed management.
What is the intellectual property status of your innovation?:
The IP is retained by the client, Bitjam focus on providing consultation and development services. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
3
Read more
Hide details
Carl Plant 20/11/2019 - 13:06 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
MyDiabetesMyWay is a proven, scalable, cost-saving self-management platform/app empowering people with diabetes to take ownership of their disease, data and treatment; delivering tailored support from NHS health record/ home recorded data.
Overview of Innovation:
MyDiabetesMyWay (MDMW) has been running since 2008 in NHS Scotland ,and is now being implemented in NHS England (e.g. Somerset, Manchester, NW London). MDMW is a cost saving (ROI>4:1) online web-based platform with over 50,000 registrants (covering all types of diabetes) funded by NHS/ government, giving patients access to their institutional (NHS) health records, integrating with home-recorded data, utilising algorithms and data linkage to drive highly tailored self-management advice and reports, communications tools and education resources.

MDMW has peer reviewed published evaluation and is an international exemplar having won many quality awards e.g. European ehealth adopters award (2017)/ Diabetes UK self-management award (2015)/ UK Quality in Diabetes Care award (2013). MDMW impacts on clinical outcomes e.g.HbA1C, is low cost (£1-2 per population patient per year license) and offers savings through reductions in complications/ efficiencies in care for NHS providers, and can be rapidly scaled across regions and countries.

THE PRODUCT:
MDMW is a portal/app encompassing:
  • >200 digital educational resources (text, video, interactive content)
  • Patient electronic health record access (institutional NHS data)
  • Patient self-management decision support with data-driven tailored advice/web links
  • 6 QISMET accredited structured education courses (GDM, Type 1, Type 2)
  • Personalised care planning documents
  • Personalised care quality reporting (e.g. DUK 15 Care Measures)
  • Patient goal-setting tools
  • Communication tools; secure messaging with health care team/ peer discussion groups
  • Remote glucose monitoring support (community upload and sharing of home blood glucose (sugar) readings and feedback).
  • External social media channels
  • Responsive and accessible web/mobile platform design
"Patient access to diabetes records through My Diabetes My Way has meant a step change in the care and understanding of my condition to a level that it has never been. I am much more in control of my condition but importantly I now understand the goals that I should be achieving and am able to have a constructive discussion with my consultant. "

MyDiabetesMyWay is now being rolled out in sites across NHS England.

MyDiabetes Clinical is a complementary clinician facing platform delivering a EHR, automated clincian guidance driven support, and individual and population analytics

http://www.mywaydigitalhealth.co.uk/
E: david.garrell@mwdh.co.uk
M: 07739 529737
E: debbie.wake@mywaydigitalhealth.co.uk
M: 07904154101
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Digital health
Benefit to NHS:
MyDiabetesMyWay is a novel patient facing intervention which can directly impact on clinical outcomes, quality of life, and improve efficiencies in service delivery. Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population. Good patient self-management driven by education, empowerment and motivation is key to good outcomes. Diabetes spending may rise over 10 years to c. 17% of the NHS budget.

People with diabetes only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; i.e. - blood glucose monitoring, medication adjustment, appropriate daily foot care, weight management and dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/ vascular disease, mental health disorders, sexual dysfunction and neurological complications.

MyDiabetesMyWay delivers cost savings and better outcomes for patients (ref: published evidence), it also improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. Regular knowledge updates, feedback on results, motivational support and flexible access to health care staff are key to supporting patients, reducing costly clinic visits, hospitalisations and death due to secondary complications, leading to longer healthier lives with significantly reduced costs.

Technology approaches in diabetes care work well, particularly if they are personalised. Low cost population based solutions are appealing in the current climate of rising prevalence on a shrinking NHS budget. Long-term conditions management needs to evolve to reap the potential benefits of data driven approaches. There is massive potential for wider lifestyle/home monitoring/institutional big data analytics to drive push notifications and automated decision support in real time to patients, which could transform care delivery. Our product development supports this evolution.

MDMW can contribute to the local implementation of the NHS Long Term Plan. EG:

3.81 supporting delivery across primary care to enable more to achieve treatment targets
5.9 & 5.13 People seamlessly empowered by digital tools information and services/digital structured education.

Demonstrable through Tests 2/3/4 (£ releasing/reduce demand for care/reduce of unwarrant)

 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population over the age of 16. Good patient self-management driven by flexible access to good quality information (available in a range of languages), structured education courses, empowerment and motivation is key to good outcomes. MDMW supports achievement of local 3 treatment (BP, cholesterol and HbA1C) and structured education targets.

People with diabetes (PWD) only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; includes blood glucose (sugar) monitoring, medication adjustment, appropriate daily foot care, weight management and correct dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/vascular disease, mental health disorders, sexual dysfunction and neurological complications.

MDMW delivers cost savings and better outcomes for patients and improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. This combination of empowered PWD and practitioners with a more complete picture can lead to more frequent co-production of health with the patient at the heart of decision making.

Digital Health Innovations - MDMW can deliver in the following categories: 
  • Health Maintenance – MDMW is a patient support platform for those with diabetes and the combination of data linkage/their own data and information/structured education enhances motivation to self-manage.
  • Access – by accessing their records and data remotely patients can choose to access health care, we have a clinical system just starting to deploy which can further enhance this.
  • Pathways – as we build (in collaboration with the local diabetes services) a website containing all local services and which acts as the access point to all the assets in MDMW we act as a signpost to patients (we do not provide real time capacity information at this point).
  • Integration/data visualisation - this is a strength of My Way Digital Health – we specialise in data integration and provide this to patients and health care professionals in different ways. The patient visualisations are particularly powerful and helpful. E.g. 90% of patients report an improvement in the quality of their consultations as a result of using MDMW.
Current and planned activity: 
MDMW is currently deployed throughout NHS Scotland. MyWay Digital Health are now implemented/ing MDMW in sites in NHS England, including Somerset, NW London and Greater Manchester. We were selected as one of 11 NHS innovation accelerator programme fellows (2018 cohort) and the Digital Health London accelerator, both of which are supporting adoption.

We continue to develop the product including Artificial intelligence/machine learning, decision support and a corresponding clinician platform through Innovation funding.

This will further enable delivery of the long Term Plan and section 5.29:

"Decision support and AI ... technologies need to be embraced by the NHS, but also subjected to the same scrutiny that we would apply to any other medical technology. In the coming years AI will make it possible for many tasks to be automated, quality to increase and staff to focus on the complexity of human interactions that technology will never master.
See files for company skill profile.
What is the intellectual property status of your innovation?:
Intellectual Property for MDMW is fully assigned to the company from the University of Dundee for exploitation.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Regional Scalability:
Implemented at scale across NHS Scotland since 2008 (currently> 35,000 registrants), Implementing in Somerset CCG and across NW London STP. Working on applications in Greater Manchester and other areas.
Measures:
Previous Assessment in NHS Scotland:

MDMW clinical impact has been assessed (April 2017) using time-series analysis comparing HbA1c of active users with those in the inactive background patient population (control cohort) matched by age, duration of diabetes, socioeconomic status and gender (7147 interventions (registrants and active users) vs 36020 matched subjects). My Diabetes My Way (MDMW) users demonstrated a sustained 4 mmol/mol HbA1C reduction. Further health economic analysis based on UKPDS complications models and £1 per diabetes population annual charge/ 5-10% registration, suggests a return on investment of around 6:1. User surveys; 90% feel MDMW supports diabetes knowledge, self-management and motivation.

Ongoing Assessment:

- Identifying strategies/ barriers for successful implementation and uptake.
- Gather feedback on new product feature to assist in ongoing product development
- Assess changes in health outcomes, complications prevention and health economic benefits 
- Assess changes in working practices/ care delivery efficiencies e.g. impact on consultation numbers, face to face education, unnecessary screening tests

*Outcomes will be added to the health economic model
Adoption target:
We would aim to offer to everyone in the region with diabetes and rapidly onboard 5-10% of the entire diabetes population in your area in the first 12 months. Our intervention USP is low cost and scalability (at no additional per person cost).
Read more
Hide details
David Garrell 18/09/2019 - 14:58 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Improve Compliance to medication by having an add on Smart sensor that will provide feedback to the patient when they have not taken or not taken correctly the medication. Thus impoving outcomes and driving down costs on the healthcare system.
Overview of Innovation:
Aptar has developed an add on sensor that is designed to sit on the top of a pressurised metered does inhaler.
Adherence and compliance in Asthma patients is notoriously low. It can be as low as 40%. The job of the sensor is to give patients contextual reminders to ensure they take their medication and they take it correctly. Should they not take their medication correctly they will suffer symptoms, an exacerbation leading to hopsitalisation and potentially death.
In addition to the reminders, it can also give feedback to the patient on their inspiratory flow rate this enabling the patient to have more understanding on how the medication is improving inhalation.
The data can be collated and shared with the physician at their regular checks.
So the system will improve the lives of patients and also help to drive down the cost on the healthcare system.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The system is a low cost reusable device. Its use is expected to reduce the number of incidents related to Asthma patients. A reduction in the number of patients ending up in hospital will have a significant reduction in cost on the healthcare system. It will free up spaces in hospital. In addition to this, if patients become more compliant the way they are managed as an outpatient in the community can be modified with less reliance on face to face visits.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
The system is a low cost reusable device. Its use is expected to reduce the number of incidents related to Asthma patients. A reduction in the number of patients ending up in hospital will have a significant reduction in cost on the healthcare system. It will free up spaces in hospital. In addition to this, if patients become more compliant the way they are managed as an outpatient in the community can be modified with less reliance on face to face visits.
Current and planned activity: 
We do not currently have any plans with NHS stakeholders. Our desire is to get an initial engagement with NHS stakeholders to demonstrate the effficacy of such a device and then move to implementation phase.
What is the intellectual property status of your innovation?:
Aptar owns the IP and has an FTO.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Read more
Hide details
Marcus Bates 13/08/2019 - 16:26 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Caburn Health integrates IoT technology solutions for health and social care to enable patients with long term conditions to stay safe and well in their own homes.
Overview of Innovation:
Caburn Health develop and deploy technology solutions for integrated health and social care provision, answering the challenges set by aging populations and ever more thinly stretched budgets.

Our Home Hub allows simple connection of authenticated health, social care and home automation devices using open industry short range wireless standards to create a single view of the patient’s wellbeing, the environment around them and how they are interacting.

Scalable and future-proof
Our major focus is in delivering simple to use, stand-alone, highly extensible monitoring and reporting systems based on open industry standards to ensure future relevance and interoperability with existing technologies.

Security
The secure data platform can be easily configured to direct monitored data, alerts and alarms to the relevant people and systems by any preferred method or protocol.

The benefits are enjoyed by:

Patients, who spend the maximum time in familiar surroundings, minimise or avoid acute illnesses and exposure to the risk of hospital acquired infection.
Health Services, who reduce the number of emergency admissions to over-full hospitals, and are enabled to discharge recovering patients to home more quickly freeing beds for new arrivals.
Families of patients, who are better able to monitor the care and wellbeing of their relatives with less disruption to their daily lives.

Our partners include:

Atos, who provide scale capability, logistic and systems integration support.
M2M Intelligence, who provide resilient, managed multinetwork SIMs and data services.

 
 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Digital health
Benefit to NHS:
The Caburn Health solution enables clinicians to remotely read sensors placed in the patient's home, thus reducing the need for home visits, enabling community healthcare teams to manage a greater workload and with increased efficiency.
Long terms conditions can be more closely monitored and the instances of acute episodes and unplanned hospital admissions can be reduced.

Acute hospitals can further benefit by being able to discharge patients to home with more comprehensive care package in place for close monitoring during transfer of care to the community team.
Patients benefit by remaining at home for longer and maintaining stability in the management of their condition(s).
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
The local West Midlands population is aging, and incidence of Long Term Conditions ('LTCs') are increasing in line with the national trends, the Caburn Health solution can help to reduce the cost burden to local budgets of unplanned admissions to acute hospitals, can reduce 'bed-blocking' or delayed transfers of care. The local population will also directly enjoy the benefits of remaining safe and well at home for longer and reduced incidences of acute illness when managing LTCs.
Current and planned activity: 
A trial is underway with the NHS in Scotland, on the Western Isles, in conjunction with Atos Consulting UK which is running in parallel with curent practice to establish a baseline and to prove the technology. A full analysis of the results will be available at the end of the trial (late 2019 / early 2020). During 2019 / 20 further trials are in planning stages for across the UK, and EU.

In addition to trials with NHS Western Isles focused on long term physical health conditions, Caburn Health is also working with research teams from Sheffield and Oxford Universities to evaluate the use of IoT technology in the management of Mental Health conditions. This is at an early stage of defining requirements and scoping the structure for the investigations.
 
What is the intellectual property status of your innovation?:
Caburn health have built a device management platform (copyrighted code) that enables the operator to monitor the connected state of each Hub and to verify any peripherals attached to it. Parameters such as battery life, connectivity (3G / 4G), sensor calibration status etc. are reported back to the platform in near real-time.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Matthew Owen 22/07/2019 - 10:38 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
EverInspire –introducing a unique way to think about mental health and wellbeing through the innovative Uni-being model.  Our evidence-based programs help organisations offer a cutting-edge wellbeing provision for their staff.
 
Overview of Innovation:
EverInspire Ltd is an online platform that uses the latest scientific research to design innovative programs that can positively impact mental health and wellbeing.  When adopted by organisations as part of their staff wellbeing provision, EverInspire’s programs can positively impact important metrics such as engagement.  Our RCT has also shown that our programs can significantly impact depression, anxiety and stress.

The EverInspire business model operates through three strands.

1. EverInspire Workplace is a subscription service provided through a LMS.  Once subscribed organisations gain access to evidence – based programs designed to improve individual and whole organisational wellbeing.  The digital aspect allows the programs to be disseminated widely at low cost.  These programs can also be licensed and hosted on the organisation’s LMS.  Research has shown that people would prefer to access wellbeing programs digitally and research into effective digital interventions is still in its infancy - this is where we aim to innovate.

2. EverInspire Public is a ‘free upon entry’ platform that facilitates interactions between wellbeing professionals (e.g. researchers, therapists or coaches) and the public. It does this by offering offering a directory of wellbeing professionals plus access to our online programs designed for the general use.  Our professionals are specialist Positive Pscyhology Coaches who have obtained or currently studying for a Master's in Positive Psychology Coaching. We check credentials such as qualifications, insurance and ICO registration.  Our professionals receive training on the protection of vulnerable adults and know when to signpost to specialist support.  The products on EverInspire are only available to working age adults. 

3. EverInspire is also a social enterprise and allocates 51% of our profits for our social cause. 
   
Our professionals can contribute material to the platform, however all material is curated by EverInspire. This includes a thorough check of the evidence base.

We introduce our clients to the research based Uni-being model, which is designed to help organisations and individuals understand the whole spectrum of mental health and wellbeing.  The model helps to identify individual or organisational strengths and weaknesses for wellbeing and aids discussions about where one could choose to focus their attention. 

EverInspire has a strong focus on research, evidence, client choice, collaboration, creativity and safety.



 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
By using a research-based approach to supporting mental health and wellbeing, EverInspire has the potential to focus its resources on the most optimal ways to improve mental health in society.  The cost of poor mental health to the economy in the UK is estimated to be about £99 billion, with 300,000 people leaving work each year due to poor mental health.  The NHS is often the first point of call for people who are experiencing difficulties.  EverInspire focuses its research on preventing distress and the building of psychological resources, which can in turn lead to people needing less support from the NHS.

EverInspire is focused on producing digital solutions that are effective and can reach people at scale.  Research into the most effective digital innovations that have the potential to impact mental health and wellbeing is very much still in its infancy.  Digital solutions are relatively new in the arena of mental health and wellbeing, and as such, there are many dubious websites and apps offering out-of-date advice to people who need support.  At EverInspire, we believe we have an urgent duty to the public to research and test efficacious interventions that can be offered online.  It is also important to understand the impact of practitioner support.  

Overall, we believe that the research conducted by EverInspire and ultimately the application of this research, can have the potential to positively impact societal mental health and wellbeing, thus reducing the burden on the economy and in turn the NHS. 
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
Our innovation has the potential to be delivered at scale, however being a West Midlands based business, our efforts will be focused on reaching out to West Midlands based organisations first and foremost.  By supporting West Midlands SME's, we hope to have a positive impact on employee wellbeing, engagement and productivity and thus the health and wealth of people in the West Midlands.  
Current and planned activity: 
The EverInspire platform is an early stage start up.  However, our immediate plans involve reaching out to West Midland's based SME's and continuing with our research.  We are currently reaching out to SME's to initially test our programs on a small workforce and receive further feedback and evaluation of the Uni-being model.  The Uni-being model and the accompanying programs have been subjected to a RCT, however further qualitative evaluations and feedback is very much required.  
What is the intellectual property status of your innovation?:
We have just been accepted on to the IP enabler program with Innovation Birmingham and John Cooke. This will help us to identify and protect our IP. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Laura Byrne 08/07/2019 - 13:21 Archived 3 comments
0
0
Votes

Innovation 'Elevator Pitch':
Modul-Bio provides a biological data management software specifically designed for biobanks and cohort projects. Main functionalities include patient management, samples collection, processing, distribution and disposal.
Overview of Innovation:
MBioLIMS BioBanking®
 
Modul-Bio solutions allow users to manage the complete lifecycle of biological material and related data. MBioLIMS BioBanking® is dedicated to the management of samples and associated data and is modular and evolutive allowing the expansion and fit of the system to match laboratory requirements..
The whole system is intuitive for end-users, flexible for customization, easily scalable even in a multi-site environment, accepts plug-ins for applications or equipment such as laboratory instruments, robotics or storage, and ensures long term data security.

Access to the application is via a local Browser with no installation required on individual computers. The setup of the system facilitates confidentiality with secured data transmission on HTTPS, and is VPN compatible. MBioLIMS BioBanking® can be installed locally, or as a cloud solution to fit client needs.

It is possible to specify the level of access of each user by creating new profiles with specific roles. It is also possible to show/hide nominative data. Each site can have an internal administrator, trained by Modul-Bio’s team to manage and evolve the solution as required.

A complete Audit Trail is embedded within MBioLIMS BioBanking® which records all actions taken including user registration, who performed the action (create, modify, delete), date and time, fields and values that have been modified. This covers sample movement, transformation to end points such as destruction to provide traceability and information that can be used in reports, audits and business improvement.

Sample storage and movement is fully monitored and storage containers can be designed and edited by system administrators. This allows the client to replicate the laboratory space within the system, monitor and report sample movement and custody. Storage can be assigned to certain studies, or restricted to particular sample types to prevent incorrect use of space. If samples are transferred to other facilities, or external contacts the shipment and manifests of these activities can also be created and controlled within the application. The interface provides a visual representation of the storage system that allows users to navigate all freezers, nitrogen tanks as well as their content all the way to the details of the sample container (tube/plate/2D rack, etc.)

Many other modules are available, and more are developed each year to match biobank requirements.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
MbioLIMS provides a specific solution for biobanking laboratories and projects. This facilitates the management of the patient and sample data, and generates viable sample / metadata for research. It can also be connected to eMBIOBANK, a web catalogue for research use.
NHS data can be stored securely, or held outside of the MbioLIMS application and linked by an anoymous unique identifier. In either case, samples and derivatives are linked to the information required.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
Modul-Bio is commited to providing a benefit to all client locations, but has resource locally to the West Midlands.
Current and planned activity: 
MbioLIMS is already used in the UK, with NHS data integration as needed. Modul-Bio is continuing to expand both UK and International clients with the required connection to patient registeries.
The application is designed to improve biobank management, sample custody and viability to promote more utilisation and research for increasing patient well being.
What is the intellectual property status of your innovation?:
The Software and any authorized copy are the intellectual property, the valuable trade secrets and confidential information of the Service Provider who owns the relevant rights. The Software is protected by law, including without limitation the copyright laws of France and other countries, and by international treaty provisions. The Service Provider does not assign any property right when licensing its software solutions and reserves all rights not herein granted. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
MBioLIMS has an available compartmentalisation module which is designed for scalability across regions (or even countries) so that different laboratories can access the same instance when working together.
Modul-Bio has previously implemented solutions within the same regions and once inbedded can facilitate user groups and collaboration.
Measures:
Modul-Bio has designed MBioLIMS to improve biobank processes, sample custody and managment. The system is focused on faster and more thourough management and processing. We do ask current clients for reviews and identified ROI's.
Adoption target:
Target clients are hospitals, universities and private organisations that host a biobank.
 
Read more
Hide details
Mike Woodward 01/07/2019 - 12:27 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Pressure releif app on vital packs
Overview of Innovation:
I am a student nurse who is currently developing an assignment on an innovation. My idea was to introduce a pressure releif system on the vital packs similar to the presentation for observations. I have observed in practice how it is difficult to keep on top of the different times different service users need pressure releif. I beleive this system would be an advantage not only for service husers health but for the staff on the ward as they will know when pressure releif is due for a service user by teh same alarm as the obersrvation. I beleive this improve service users health by also preventing the risk of DVTs and onitoring any skin deteriorationwhilst keeping a simple system throughut the day which is easy to follow. I also beleive this would be a simple addition to the vital packs which is cost effective. If anyone is able to read this and give me any tips or ideas how I could go about inventing this, or finding someone to contact I would be very greatful!
Stage of Development:
Ideas stage - Early concept and ideas stage
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Digital health
Benefit to NHS:
Help prevent pressure ulcers by keeping on top of pressure releif which would help reduce costs of treatment. Using staff more effectively and the vital packs already invented which will also help with time management. 
Benefit to WM population:
Again by reducing the number of pressure ulcers which arise in hospitals 
Current and planned activity: 
I have only thought of this idea for an assingment as i am a student nurse. However, I would be very greatful if i could get help on who i could contact to talk about this or implement this in the future
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Chelsea Smith 11/06/2019 - 16:06 Sign Posted 1 comment
0
0
Votes

Innovation 'Elevator Pitch':
  • 2.074 Care hours Saved Per Day
  • £20.84 Saved per Day
Even if 10% of those receiving long term care were introduced to grandCare, that would mean a potential saving to Local Authorities of £1.8 Million PER DAY!...or £657m per year.
Overview of Innovation:
GrandCARE is a touchscreen device filled with a number of features.

Figures issued by the Adult Social Care Activity and Finance Report showed that 857,770 people received long term care support from Councils in 2017-18.  Local Authorities pay an average of £15.52 to external care providers for one hour of home care.
 
grandCare has just finished reviewing the results of a twelve-month pilot for a local Council. Each user was supplied with a grandCare unit and a mixture of sensors with the aim to
  • Improve safety
  • Empower independence, choice and inclusion
  • Making independent living more sustainable
  • Providing services in an increasing cost-effective way
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Proven recorded fall reductions of 66% in a care home environment.  This can be replicated throughout the NHS
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
Reduced number of falls, less hospital re-addmissions, touch screen technology to allow family and care givers to securely communicate reducing loneliness, medication prompts and reminders, videos to help with normal household tasks (cooking etc).
Current and planned activity: 
We've met and are working with the QE Hospital in Birmingham to potentially carry out a large fall reduction trial.  Our main customer base are currently local authorities, but the NHS is certainly a road we see huge benefits for.
What is the intellectual property status of your innovation?:
copyrighted
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Scott Walker 11/06/2019 - 15:48 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Sensium Wireless Vitals Monitoring is proven to lead to treatment of sepsis 6 hours quicker than NEWS, reduce LOS by 10% and readmission by 45%. The only wearable vital sign monitor with peer reviewed RCT data showing significant clinical benefits. 
Overview of Innovation:
In general care areas of a hospital vital signs are typically taken during routine observation rounds once every 4-8 hours. If a patient deteriorates between these observation rounds the warning signs can go undetected for hours, potentially leading to serious & costly consequences. 
 
Sensium is a discreet, wearable, wireless system for monitoring vital signs of patients outside of high acuity areas. A light comfortable sensor worn on the patient’s chest accurately and reliably monitors and reports vital signs, providing data every 2 minutes. By notifying clinicians of changes in patients’ vital signs Sensium brings the nurse to the deteriorating patient, allowing intervention before the condition worsens, thereby improving patient outcomes, shortening hospital stays and lowering treatment costs. It enables nurses to prioritise patient care where it is needed most.   Sensium is focussed exclusively on general care clinicians whose patients currently do not have the safety and security of continuous vital sign monitoring.
 
The Sensium Patch provides accurate and continuous monitoring of the 3 key leading indicators of patient deterioration: heart rate (HR), respiration rate (RR) & axillary temperature (T). Sensium wirelessly communicates this physiological data via safe and secure low power wireless communication to the Sensium bridges placed through the ward area.  Sensium allows patients to ambulate freely, untethered to static and expensive equipment whilst still having the reassurance of continuous monitoring.
 
The bridges are connected into the hospital IT system, and software installed on the hospital network allows patient data to be seamlessly conveyed. Crucially, notifications can be configured to work with hospital pager systems/mobile notification devices, giving the clinical team data when they need it, where they need it. To save time and ensure accuracy Sensium can be easily integrated with the hospital admission, discharge, transfer systems and electronic medical records.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Currently approximately 10% of patients are harmed during their hospital stay and this represents a cost to the NHS of over £2.5bn just to cover the additional length of stay for these patients. Improved monitoring regimes and early detection of deterioration is key to reducing this significant burden.
 
Patients undergoing major abdominal surgery have an 30-40% risk of complications with a leading complication being sepsis. Hospital acquired (HA) sepsis (e.g. sepsis that develops after a surgical procedure) has twice the mortality rate and twice the treatment cost of community-acquired sepsis and rates of HA sepsis are rising. A recently-published study aimed to assess differences in outcomes between patients being monitored using the Sensium system in addition to intermittent (routine) observations and patients being monitored by routine observations alone [1].  The study was designed as a pilot cluster-randomised, prospective, parallel-group, controlled single-centre pilot study and consenting participants were allocated to one of two monitoring arms for the length of their admission. The primary outcome measure was time to antibiotics after the first evidence of sepsis, defined according to a revised consensus conference definition in 2001 [2]. Secondary outcome measures included length of hospital stay, 30-day readmission rate, mortality and patient acceptability. 226 patients were randomised between January and June 2017. 140 patients were randomised to continuous remote monitoring; 86 patients were randomised to receive intermittent monitoring alone. There were a similar number of complications and sepsis events across both arms of the study, indicating that both groups had similar baseline risk factors.

On average, patients receiving Sensium continuous monitoring were administered antibiotics 6.4 hours sooner after evidence of sepsis, had a 10% shorter average length of hospital stay and were 45% less likely to require readmission within 30 days of discharge than those patients in the intermittent monitoring group. Patients found the monitoring device to be acceptable in terms of comfort and perceived an enhanced sense of safety. Given that every hour’s delay in treatment of sepsis has been shown to be associated with a 7% increase in risk of mortality [3], a 6-hour reduction in time to administer antibiotics is a significant result and further studies are ongoing to demonstrate similar benefits in other clinical settings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Sensium’s solution offers several key benefits to the West Midlands and its population. The key benefits of Sensium compared to competitor products are as follows:

Product Performance: Sensium uses clinically accepted ‘gold standard’ methods of vital sign measurement, deriving heart rate from single-lead ECG, respiration rate from thoracic impedance, and temperature from an axilla sensor.  In contrast, our competitors derive respiratory rate from pulse or ECG measurements which has known limitations in certain clinical conditions and provide only skin temperature measurement which has limited clinical value.

Customer Focus: Sensium is recognised by our customers for exceptional customer support.  Once we deploy our product at a clinical site, we provide on-site technical support for installation and troubleshooting and clinical support for training for as long as it takes for the system to be truly embedded in the clinical workflow and providing tangible benefits. Sensium has clinical and technical staff based in the West Midlands region on hand for support.

Clinical Evidence: Sensium understand that medicine is an evidence-based science and we are engaged in a series of clinical research studies designed to show clinical efficacy, improved clinical outcomes, and health economic benefits.  To date, Sensium are the only company providing wearable wireless technology for early detection of patient deterioration that have independent and peer-reviewed publications showing benefits of our technology demonstrated through randomised controlled trials
 
 
Current and planned activity: 
Our initial engagement with the NHS has been to introduce Sensium to general surgery wards and areas with high risk and infection prone patients e.g. colorectal, trauma and haematology wards. Discussions with many NHS hospitals have also shown significant interest and benefit for the use of Sensium for ‘Step down’ areas for patients who aren’t sick enough for ITU but still show cause for concern and for high risk conditions such as Hospital Acquired Sepsis opioid depression and AF. 

We have engaged with the Emergency Laparotomy Collaborative with a view to patch these types of patients. When approaching the NHS, we have been primarily engaging with Anaesthetists as they witness many patient deteriorations, as well as consultants and sepsis/patient deterioration leads, matrons and clinical IT leads. We plan to interact more directly with medical directors and members of the directorate earlier on in the process if possible. Future plans include home monitoring to follow patients’ home.
What is the intellectual property status of your innovation?:
CE mark and FDA 510(k) cleared.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
2
Co-Authors:
Read more
Hide details
Sonia Hussein 18/05/2019 - 11:34 Publish 4 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Enabling patients to self-rehabilitate with clinically evidenced treatment plans to improve the speed of recovery and enhance patient outcomes. Reducing unnecessary prescription of medicines, scans and surgery; along with GP and Physio workloads.
 
Overview of Innovation:
Rehab Me offers GP’s a tool to help advise and support their patients without necessarily referring them to a physio for a scan or prescribing pain medication. It provides easy to access evidenced based advice sheets, treatment plans and interactive prompts to support compliance and outcome tracking, as well as signposting patients to further support and prevention pathways.
 
How it works: A simple digital solution, accesses on-line or via a downloadable all which operates on a stand-alone basis or be integrated into existing GP systems.
 
Step 1 - patient injury or MSK condition identified by GP who then prints off the relevant advice sheet from the Rehab Me website. This provides evidence-based exercises and advice regulated by standard physiotherapy practice and directs patient to the Rehab Me website for the patient to register.

Step 2 - patient registers on the Rehab Me website and selects the treatment plan advised by the GP. This will then provide scheduled exercises including frequency and number of repetitions across the treatment plan period. This is automatically linked to the patient’s calendar to enable reminders and prompts over the treatment period which can be anywhere between 6-10 weeks.
 
Step 3 - the patient can access the plan via the website or a downloadable app. The patient will be prompted each day and guided by their virtual physio with the use of easy to follow HD videos and/ or detailed descriptions.  Patients track their own adherence and progress through the website or via the app. They can also record and track pain each day to help assess progress and provide PROM data for their GP.
 
Step 4 – at any time the GP can view progress and results for a patient on a treatment plan; and if appropriate advice on a new exercise plan virtually so the patient can progress without the need for another appointment.
 
Step 5 – during or after a course of treatment, Rehab Me can signpost access to other relevant resources to encourage people to adopt exercise into their everyday lives to prevent relapse. This includes a social prescribing section encouraging patients to join gyms, walking clubs etc.
 
Part of the service provided by Rehab Me includes educational training on MSK issues as part of the process to this new pathway for GP’s to adopt in their practice.

The Rehab Me data platform adheres to appropriate NHS data IG and GDPR requirements, with all data securely stored on a cloud based server.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
The Rehab Me solution has been proven to:
  • Reduce unnecessary prescription of medicine
  • Reduce the need for costly scans and potential surgery
  • Reduce demand on physio appointments
  • Improve a GP’s ability to provide relevant MSK advice
  • Improve patient activation and compliance
  • Improve waiting times for specialist physio appointments
  • Support First Contact Practitioners in GP surgeries.
 
There is further opportunity for Rehab Me to reduce demand through earlier preventative treatment, on-going self-management support and improvement in post-surgery recovery and potential length of stay in hospital.
 
The results: a structured 18-month proof of concept across five GP practices servicing c70,000 people resulted in 2300 patients being supported, achieving the following key results.
 
  • 89% of GPs said they are now ‘confident’/ ‘extremely confident’ in managing MSK issues, versus 33% at the start
  • 70.3% of GPs recommended over 50% of patients to Rehab Me rather than referring to a physio.
  • 30.8% of GPs reduced prescribing medication by 50%
  • 25.9% of GPs reduced referral for imaging (XR, USS, MRI)
  • 19.2% reduced prescribing medication by 70% for MSK conditions
  • 50% improvement in patient pain scores, average score of 3/10 to 6/10
  • 66.7% of GPs rated the pilot 10/10 (with 10 = fantastic)
  • Reduced physio waiting times, from over 7 weeks to just 2 weeks for patients
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
For Patients
  • Immediate and faster recovery time
  • Improve health, well-being and pain management
  • Increased confidence and empowerment to re-habilitate.
  • Reduced inconvenience and travel time for appointments
  • Avoid risks and side effects of anti-inflammatories, analgesics or other medications    
  • Potential surgery avoidance or painful injections
  • Easy and convenient solution access.
For GP’s
  • Increase knowledge and confidence to support patients with MSK conditions
  • Reduction in prescribed medicines
  • Reduction in physio referrals
  • Reduction in imaging and consultant referrals
  • Reduction in GP appointments
  • Ability to track patient activation and PROMS
  • Increased practice efficiency.
For NHS Physiotherapy clinics and other referral departments
  • Reduced number of referrals
  • Reduced wait times to enhance intervention effectiveness
  • Improved prioritisation of serious patient referrals
  • Enhanced quality of service and care
For Commissioners
  • Better resource utilisation
  • Increased capacity at lower cost
  • Alignment to the GIRFT programme
  • Strong ROI based in increased capacity and reduced medication / scan costs
For the Economy
  • Local employment - potential to build software development team locally
  • Local office - commercial office space
Current and planned activity: 
The Rehab Me solution has been supported By NHS England through its Clinical Entrepreneur programme and identified by Dr. Tony Young, (National Clinical Lead for Innovation) as a lead example of a new and exciting digital solution for scaling across the NHS.
 
The Rehab Me platform has been developed to Beta release level and is now ready for further development to ensure a robust and scalable software solution which can be easily integrated into other NHS systems.
 
The next stage requires effective engagement with appropriate PCN or GP Federations or CCG to secure financial commitment to embed the solution, support its development and assist in further case study creation and cost benefit analysis. This will then enable a comprehensive sales and marketing drive across England.
What is the intellectual property status of your innovation?:
Copyright of all content owned by Surrey Physio along with software design
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Mark Doorbar 13/05/2019 - 09:41 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Amplitude pro enterprise™ uses simple technology to capture clinical and outcome data for specific diseases, diagnosis, interventions and care pathways. Data is retained locally and available for immediate reporting and analysis.
Overview of Innovation:
The Amplitude pro enterprise™ software is a simple, tailored online platform centred around two crucial elements:
A user-friendly electronic patient portal which gives patients the freedom of completing their scores online at home, on site and via various devices and a consultant dashboard giving the clinician(s) the ability to input patient specific complexity factors and procedure data quickly and easily.

The result is representative, accurate and meaningful data that paints a clearer picture of each patient’s level of health and expected recovery. Clinicians are engaged with the clinical outcomes processes at your hospital, you get the insight required to innovate your clinical services and patients get a consistently high standard of care.

pro enterprise™ is simple, cost effective and delivers precise and accurate data, selecting scores that are identified as important to you.

The data you collect in pro enterprise™ will allow you to monitor your service delivery, identify quality issues and demonstrate levels of care. Your hospital can be confidently transparent about its activities, resulting in reassurance to your peers that you are offering the best care possible.

Amplitude specialises in the collection of electronic PROMs and clinical outcomes and we are the leading supplier of electronic PROMs to the NHS. We are accredited by NHS Digital for the electronic capture and upload of National PROMs and our platforms have achieved the highest levels of IG compliance, using data centres that are ISO27001 certified. 

Amplitude's unique data exchange tool means that you enter and retain your data locally in your pro enterprise™ platform and the necessary data for clinical registries, National PROMs and NJR can be  pushed to the relevant databases on your behalf.

Our systems are designed to empower clinicians in adding value to their data e.g. proper case mix adjustment, log-book, revalidation report and easy analysis and self-monitoring tools. The system automates the process of data collection via a series of reminders sent to patients via email and SMS. These reminders are triggered from the intervention data which at minimum includes procedure/intervention description and diagnosis. 

Amplitude pro enterprise™ is customised and tailored to suit specific department requirements and objectives including virtual clinics, clinical outcomes and PROMs. pro enterprise™ is currently being used in T&O, Rheumatology, Urology, Cardiology and Mental Health departments.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The Amplitude pro enterprise™ system captures and manages clinical and PROM’s outcome data with the key focus to improve overall quality of patient care.
NHS healthcare professionals are required in many specialist areas, to monitor the long-term effects of treatments.  Historically, these were captured on a macro level and this mass gathering of non-specific data, results in outcomes data that is non-meaningful and without sufficient detail or context, preventing its use in making effective, informed clinical and management decisions.
In addition, due to the paper-based nature of how PROM’s and clinical outcomes were historically gathered, often, data would only be made available months after being gathered and in an aggregated and anonymised format, rendering it out of date and of little value.

With Amplitude pro enterprise™, The NHS benefits from the ability to;
  • Capture the clinical outcomes of patients in larger numbers and in an electronic format,
  • Effectively measure the quality of care provided by clinicians in real-time
  • Measure the efficacy of the treatments being used on a local, national and international level
  • Reduce costs associated with carrying out the required questionnaires in a paper format
  • Use the data gathered to compare treatment plans and ensure that patients are receiving the best possible care available
  • Increase clinical and patient compliance and engagement in outcome data collection
  • Meet the challenge to make the NHS paperless
  • Opportunity to provide multiple language options; allowing the patient to complete their electronic questionnaires in their native language instantly
  • Use Amplitude's unique data exchange tool to automatically upload required registry data when the information is gathered in the Amplitude pro registry™ platforms, thus reducing administration, duplication of effort and importantly, retains the outcomes data at the source pro enterprise™ system, allowing instant insight
  • Access to comprehensive reporting tools, that include templated validation reports for individual clinicians, further reducing resource, time and effort
Amplitude pro enterprise™ provides the NHS with a paperless, streamlined data gathering software, that reduces costs, has real-time results, meaningful insights for clinical and managerial decision makers and ultimately improves the overall quality of patient care.
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
The West Midlands AHSN covers 6 regions within the NHS; Birmingham and Solihull, The Black Country, Coventry and Warwickshire, Herefordshire and Worcestershire, Shropshire and Staffordshire.

Within this area, there are 33 NHS Trusts servicing the needs of a population of approximately 7.225 million (ONS 2017). According to the ONS, 18.2% of the population were aged 65 years and over.
It is also documented that over half (54%) of older people have at least two chronic conditions increasing to 69% among those aged 85+ (Kingston, et al., 2018).
Multi-morbidity increases the likelihood of hospital admission, length of stay and likelihood of readmission, raises healthcare costs, reduces quality of life, and  increases dependency. (Kingston et al., 2018).

These are all operational factors being faced in the West Midlands region and the implementation of innovative technologies, to help manage the growing dependency on the NHS, are essential.
The implementation of Amplitude pro enterprise™ will not only allow for monitoring outcomes, it can also use the outcomes data to manage workloads, triage clinics and help to influence operational management. 

Eg; fracture clinics see all patients admitted to A&E with musculoskeletal problems, the system could reduce the number of follow up appointments in Trauma and Orthopaedics clinics by assessing cases in a virtual clinic, prioritising the appointments of patients that require surgery or a clinic appointment and booking those that are less urgent into follow up clinics.

Or: The Amplitude pro enterprise™ platform can provide the method of prioritising more urgent cases in Rheumatology or Cardiology clinics, allowing urgent cases to be seen ahead of patients who are performing well with their current ongoing treatment plan.

Managing the patients according to need and not by pre-set time frames, could help to prevent potential A&E visits by patients who deteriorate or do not respond as expected to their treatment plans.

Administrative workloads can be reduced, and the overall quality of care provided to patients can be dramatically improved, whilst overall cost savings are obtained as a result.

In addition, administrative productivity can be increased with the data exchange tool. For mandated registry data submission such as National PROMs, NJR and now BSR (Apr 2019), data is entered just once and the Amplitude pro enterprise™ platform uploads the relevant information as required, with the data being retained for local analysis.
Current and planned activity: 
With a wealth of NHS experience in the Amplitude team, the products we design and develop have NHS priorities and needs at the heart. When the pro enterprise™ platform is deployed into a hospital or trust, the Amplitude development team continue to improve the system to best service it’s users. Upgrades are released annually, upgrading the functionality on a regular basis.

CCG’s are looking at commissioning based on outcomes and lucrative contracts are sent to the trusts and hospitals with the best results. pro enterprise™ ensures boards can evidence their results to win these contracts, adding funding to budgets.

pro enterprise ™ promotes interoperability. The ability to receive data via exchange from a growing number of PAS’s is a major factor in reducing administrative workload and costs, but when this technology is combined with the ability to also push the data (electronically) to populate the associated registries too, the benefits and cost reductions are multiplied.
What is the intellectual property status of your innovation?:
Amplitude Clinical Outcomes own the intellectual property rights on this platform.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Sarah Steptoe 16/04/2019 - 10:58 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ChatHealth is a messaging helpline to enable service users to securely contact a healthcare professional, supporting timely, confidential access to help. 
Overview of Innovation:
ChatHealth is a safe and secure text messaging service that helps families and young people get in touch with healthcare professionals. First developed by school nurses at Leicestershire Partnership NHS Trust (LPT), ChatHealth supports greater efficiencies within public health community nursing teams, with individual nurses able to provide for a greater number of service users. It is cost effective and uses technology millennials are familiar with, providing confidential and timely access to healthcare. People who need health advice and support do not need to wait for a nurse visit and the service is completely anonymous meaning it reaches out to often seldom-heard and vulnerable groups.
  • Available to nearly two million young people in England.
  • Available to the parents/carers of nearly 80,000 new-born babies a year.
  • Increased service reach/access - delivering 100 additional contacts every month.
  • Overcomes the stigma of face-to-face discussion of sensitive issues.
  • Reaches more underserved groups - 1 in 5 male users compared to 1 in 10 in face-to-face clinics.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
  • An efficient way of working for teams that are already stretched, for example one duty nurse can support large populations of people, within existing capacity, delivering up to 100 additional contacts every month. Working in more traditional ways, it would require the appointment of two additional nurses to improve reach to the same level.
  • More contact from more new service users across a broader range of issues. This is particularly relevant for certain “hard to reach” demographics, such as adolescent males, who are more likely to ask for health advice and help by sending a message compared with traditional forms of service access.
  • ChatHealth is a sustainable solution.  Environmentally, it reduces travel, particularly in rural areas where nurses might otherwise drive up to 90 minutes to visit a particular school. 
  • Due to how ChatHealth changes the model of delivery, resources can be better allocated and promote more effective spend of taxpayers’ money.
  • Strengthens and complements the universal face to face support offered by Public Health/School Nurses and Health Visitors through a digital offer which could be integrated with other services such as CAMHS, Speech and Language Therapy, nutrition and dietetics.
  • Improved access to healthcare for more children and teenagers/parents and carers who would be reluctant to engage directly with health professionals.
 COST EFFICIENCIES EXAMPLE
With safety/security assured, nursing teams can now easily provide industrial scale messaging enquiries services delivering more contact withing existing resources.  Adopting teams usually move to a single point of access model, so just one duty nurse can handle all messaging enquiries from an entire school population, usually only impacting around 0.5WTE capacity.

In a modest example, one public health/school nursing team runs its messaging service with 0.5WTE staff from within existing capacity or a vacant post, at a combined cost (salary and product licensing) of £10k less than a WTE post.  The nurse running the service supports an entire population of up to 85,000 pupils and delivers 50 contacts p.c.m.  These low-cost additional contacts eliminate unnecessary face-to-face contact (more resource intensive, more costly to taxpayers). They say it would take four more staff to deliver the same number of additional contacts face-to-face, costing £150k. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Evidence shows that young people sometimes feel more comfortable and confident relaying sensitive issues via mobile technology rather than a face-to-face discussion with a healthcare professional whilst busy parents especially value its convenience. When ChatHealth launched in 2013, the number of reported young suicides were the highest they’d been in ten years with depression and self-harming doubling. Meanwhile one in five mothers suffer from perinatal mental health issues.

The ChatHealth platform is predominantly used by community health teams supporting universal care.
The majority of enquiries relate to emotional and mental wellbeing, including adolescent self-harming and low mood and maternal mental health. Some of these kinds of contacts can be significant from the point of view of safeguarding vulnerable service users and the ChatHealth model helps to safeguard risk. Other regular types of enquiries relate to adolescent sexual health, or new parents enquiring about infant health and development.
 
Children, young people and families in the West Midlands can expect to gain the following benefits:
  • Improved and more convenient access to the specialist community public health nursing service.
  • Children & young people can contact public health/school nurses during the school holidays.
  • Improved response to need which will lead to earlier intervention.
  • Improved, quick and easy access to health advice and support for children, young people and their families.
  • Swift response to text messages within the core hours of service delivery.
  • User friendly/age appropriate resources that are localised.
  • Targeted provision for more vulnerable young people and adults that may find it difficult to access services.
  • Extends service provision to service users that may have not previously accessed the service.
  • Transcripts of the messages can be copied over to the EPR where a service user has been identified, enriching the patient record. Anonymous transcripts can be downloaded as pdf’s and stored in a secure drive.
Current and planned activity: 
Around 38 NHS Trusts and organisations have adopted ChatHealth, they receive ongoing support for their licences. We are also in discussion with several organisations who are interested in adopting ChatHealth.
What is the intellectual property status of your innovation?:
All intellectual property is held by Leicestershire Partnership NHS Trust.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Anonymous 11/04/2019 - 12:56 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
A complete holistic digital outpatient care platform which enables healthcare service providers to offer virtual care remote patient monitoring.
Overview of Innovation:
VideoVisit provides a complete holistic digital outpatient care platform that enables healthcare service providers to offer virtual care (i.e. home care and rehabilitation services), remote patient monitoring, online doctor consultation and video-based online doctor appointments via online calendar booking systems or text chat/video chat module. Complete holistic digital outpatient care can be defined as combining Primary Care, Social Care, Specialized Care and Home Care. We offer full end-to-end systems branded under VideoVisit Home Care and VideoVisit Remote Care service products.



The platform consists of tools for remote care, online doctor appointments / consultations and remote patient monitoring. Virtual care allows remote caregivers to provide healthcare services, support and companionship to the elderly in their own home via video.

Online doctor appointments allow healthcare service providers to offer services online either by utilizing a chat module with text-chat and video chat functionality or by providing video-based services via online calendar booking system. Online doctor consultation allows healthcare professionals to communicate together both through more traditional text-chat or via online video calls.

Remote patient monitoring puts together welfare devices and services and shows what is going on at home at this very moment. Using the dashboard, family members, homecare professionals and service providers see in real time the summary of how the person living at home is doing. It shows for example activity, sleeping patterns, day rhythm and information about safety and service usage.

Our platform can be sold as a stand-alone solution or it can be integrated into other digital healthcare solutions. This provides endless possibilities for VideoVisit partners to utilize VideoVisit platform. In addition to VideoVisit platform, we also provide our know-how on distributing the VideoVisit platform to end customer organizations. We also provide the best references in the market for our partners: we are the only service provider who has a whole country as a reference testimony (Finland) and a customer case where cost savings in elderly care have dropped over 85% (City of Helsinki): https://www.youtube.com/watch?v=sI628Mj5UaM

VideoVisit is the market leader in Finland with a fully commercialized service offering. In the UK we are seeking a Proof of Concept trial partner to make any adjustments required and to show the value of our solution.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption
Benefit to NHS:
VideoVisit is a market leading Nordic health technology company, developing digital solutions for the home care and healthcare sectors. The VideoVisit platform consists of two modules; VideoVisit® Home and VideoVisit® Live, which together provide a unique virtual healthcare platform.

The benefit to the NHS from our service solution is our impact on:

1) Cost savings – substantial savings by replacing physical visits with remote caregiving visits via video. As an example, one of our largest customers, the City of Helsinki placed over 170,000 virtual calls while cutting down home care costs by over 80%, saving 10M€ in 2017.

2) Time savings of the healthcare professional (nurse or doctor or service provider) - one virtual nurse is capable of placing up to 60 virtual visits over one shift. The demand for virtual care grows rapidly in Helsinki which illustrates Helsinki’s goal of having over 900 virtual care clients at the end of the year 2017.



Our unique advantages are integrated services, tested outpatient care service platforms, experience and knowledge of outpatient care processes and models. With our platform, we can connect medical device data during video consultations and have system APIs that support this. As the market leader in Finland, we have completed over 50 projects in Finland.

In addition to that, our solution shows increasing value when used with patients who are elderly or with chronic illnesses like dementia, Alzheimer’s or Parkinson’s. As the majority of the elderly and chronic illness patients have restrictions and need support to take medicine and monitor food intake, this can be done cost and time effectively with the VideoVisit solution.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
The benefits we can provide to the population of West Midlands are similar to the impact shown above in terms of cost and time benefits.

The West Midlands is a region of diversity, with areas of affluence and deprivation and with established health inequalities. It's a geographically diverse region, ranging from the intensley urbanised areas including Birmingham, Stoke-on-Trent and Coventry to the rural counties including Shropshire, Staffordshire, Herefordshire and Worcestershire.

Online Consultations are part of the Midlands and East GP Forward View (GPFV) Digital Implementation Strategy.

Virtual consultation service benefits include:
  • Cost savings
  • The ability to see multiple patients over one shift
  • Minimises travel for patients (family and carers)
  • Improves networks between doctors, patients and other healthcare professionals
  • Encourages self-care
  • Reduces risk of healthcare associated infections
Video consultations can overcome geographical boundaries and provide access to services in remote areas or those with limited numbers of healthcare professionals.

VideoVisit, a market leader in Finland that provides holistic remote caregiving are looking to work with a regional healthcare provider to undertake a Proof of Concept trial to make any adjustments required for the UK and to demonstrate the value of our proven solution with elderly people and/or for those with chronic illnesses.

Current and planned activity: 
VideoVisit Ltd is actively looking to engage with regional healthcare providers for reference Proof of Concept pilot projects.

We have only just started in the UK and are keen to engage and discuss with any interested NHS or other healthcare service providers working with us to make any adjustments required for the UK and to demonstrate the value of our proven solution with elderly people and/or for those with chronic illnesses..
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Michael Haralson 18/03/2019 - 19:22 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Hospify is a health data platform built on free & trusted messaging for patients and clinicians. A free messaging app is available to all users; a team messaging platform is sold to hospitals, surgeries, pharmacos and other healthcare institutions.
Overview of Innovation:
  • Hospify is an ubiquitous health comms ecosystem that puts patients & clinicians in control of their health interactions in a way that everyone can access and trust
  • Hospify allows patients to connect with and control their communications with healthcare providers, pharmacists, pharmacos and insurers
  • Like Slack in the commercial sector, Hospify uses open standards to enables other health apps and digital services to function within an ecosystem that benefits all parties involved
  • Hospify’s unique “serverless” phone- powered network architecture allows it to scale users without scaling costs while staying compliant with all data regulations.
     
There are lots of healthcare messaging companies popping up. So what makes Hospify different?

1) A messaging platform is only useful if everyone can be on it. That’s why people love WhatsApp. For everyone to be on it, the core platform has to be free. Hospify is built on a unique serverless architecture that allows it to scale the app without scaling the costs of supporting it.  This allows Hospify to offer its core messaging, for free, to everyone, forever, without needing to monetize our users’ data or sell them ads in order to do it. 
2) That serverless structure means that we don’t store users’ data (one of the reasons that we can’t monetize it!). All the data, at least in the free, secure and compliant app, is kept on the user’s device, and only on the user’s device. This means that compliance is baked in from the start, and enormously reduces data liabilities and security overheads - which in turn helps support our ability to provide the app for free to the majority of users.
3) Hospify is really simple to use. Most of our competitors are building complicated messaging tools designed to appeal to doctors. But at Hospify our focus is on nurses and patients - the people at the sharp end of health, who want solutions that are simple and effective and don’t require a manual in order to them figure out.
4) The Hospify messaging app is only part of what we do. Hospify’s secret weapon is the HospifyHub. The Hub transforms the App’s “WhatsApp”- style experience into something that’s more like Slack, with a web portal and a desktop app that syncs with users’ phones without compromising our compliant and scalable “serverless” architecture. The Hub offers administrated groups, broadcast messaging, and data capture via messaging surveys, and is designed to integrate with and handle data from third-party apps.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Efficiency gains from simple, non-siloed comms
Reduced risk of data breach and better clinician & patient privacy
Reduced time to decisions
Fewer face-to-face follow-ups
More timely interventions
Improved patient-centric care  
Improved mobile working
Improved interdisciplinary and inter-organisational working
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
Easier access to clinical professionals
Reduced travelling to appointments
More control over personal health data
Reduced risk of health data breach
Less frustrated clinical staff!
Reduced spend at CCG level on SMS
Current and planned activity: 
Traction (App)
  • Hospify’s free messaging app is live in the Apple & Google app stores with more than 4000 sign-ups across 60 hospitals since launch in Feb ’18 and 25% monthly active users.
The Hospify App is secure and compliant for health use across the UK and EU. End users can download the FREE Hospify App via the Apple and Android app stores.  

Live Trials (Hub)
  • Unison Health: paid trial at University Hospitals North Midlands. Intention to scale out nationally to >1k branches and >500k nurses
  • Birmingham Community NHS Trust: free trial
  • Cambridge & Peterborough NHS Trust: free trial
  • Lincolnshire Community NHS Trust: free trial
  • Medway Community NHS Trust: Up to 900 users for 3 months’ free trial
  • Corby NHS Health Centre (Lakeside+): 90 users for 3 months’ free trial The GP Service: telehealth company with national reach
 
 
What is the intellectual property status of your innovation?:
UK trademarks filed; EU, Colombia & US trademarks in process.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regulatory Approvals:
When designing its message delivery and information security architecture in 2015, Hospify carried out detailed discussions with the Information Commissioner’s Office about the legislative landscape around secure messaging in health. As a result, Hospify combines cutting edge technology and powerful security with careful consideration of UK and EU rules for handling patient information, and has the following accreditations:
  • GDPR & 2018 UK DPA compliant
  • NHS IG Toolkit (2017-2018) & DSPT (2019) (Org code: 8JN92)
  • Crown Commercial Service supplier (GCloud 11)
  • ISO 27001:2017 accreditation (Registration number: 214722)
  • ICO registered (ZA239336)
  • US encryption export registered (SNAP-R ERN R11191)
 
Read more
Hide details
James Flint 11/03/2019 - 14:39 Publish Login or Register to post comments
0
0
Votes
-99999

Recent Activities

EverInspire - Wellbeing and Coaching Platform has been moved from Initial Submission to Publish 2 months 2 weeks ago
Docly enables online clinician-patient communications supported by guideline derived algorithms through text,voice, and video. has been moved from Initial Submission to Publish 2 months 2 weeks ago
SenseGuard™ - seamless monitoring of lung function for patients with respiratory conditions has been moved from Initial Submission to Publish 2 months 2 weeks ago
Bitjam: Health and social care software research and development services has been moved from Initial Submission to Publish 2 months 2 weeks ago
The Real Birth Online Workshop: addressing the barriers to effective antenatal education has been moved from Initial Submission to Publish 2 months 3 weeks ago

Active Campaigns